Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
作者: Frank JacobsenJuliane KraftCornelia SchroederClaudia Hube-MaggMartina KluthDagmar S. LangRonald SimonGuido SauterJakob R. IzbickiTill S. ClauditzAndreas M. LuebkeAndrea HinschWaldemar WilczakCorinna WittmerFranziska BüscheckDoris HöflmayerSarah MinnerMaria Christina TsourlakisHartwig HulandMarkus GraefenLars BudäusImke ThederanGeorg SalomonThorsten SchlommNathaniel Melling
作者单位: 1Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany
2General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Germany
3Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany
4Department of Urology, Section for translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Germany
刊名: Neoplasia, 2017, Vol.19 (9), pp.707-715
来源数据库: Elsevier Journal
DOI: 10.1016/j.neo.2017.06.003
英文摘要: Abstract(#br)Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence ( P <.0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was...
全文获取路径: Elsevier  (合作)
影响因子:5.47 (2012)

  • regulation 
  • Cancer 巨蟹座